Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows - USD ($)		3 Months Ended		6 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Cash flow from operating activities:
Net loss		$ (2,176,740)	$ (1,454,899)	$ (4,597,257)	$ (3,758,212)
Adjustments to reconcile net loss to net cash used in operations
Stock based compensation				728,162	442,155
Issuance of shares for services				898,025	419,217
Issuance of warrants for services, at fair value				368,352	174,976
Accretion expense	[1]				879,416
Change in fair value of derivative liabilities	[2]				20,588
Fair value of warrants issued
Changes in operating assets and liabilities:
Accounts receivable				(43,436)
Inventory				(179,430)
Harmonized sales tax recoverable				(15,580)	(19,602)
Deposits and other receivables				(11,939)	7,983
Accounts payable and accrued liabilities				182,465	(374,650)
Net Cash used in operating activities				(2,670,638)	(2,208,129)
Cash flows from financing activities:
Issuance of shares, net				1,739,943	2,340,409
Proceeds from exercise of warrants				50,835
Issuance of convertible debentures, net
Due to shareholders
Net Cash provided by financing activities				1,790,778	2,340,409
Effect of foreign currency translation				119,471	50,001
Net (decrease) increase in cash during the period				(879,860)	132,280
Cash, beginning of period				843,643	424,868
Cash, end of period		$ 83,254	$ 607,149	$ 83,254	$ 607,149

[1] See Note 5

[2] See Note 6